Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosomepositive acute lymphoblastic leukemia

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1081-1088

  Yoon, J H ^a,b   Yhim, H Y ^c   Kwak, J Y ^c   Ahn, J S ^d   Yang, D H ^d   Lee, J J ^d   Kim, S J ^e   Kim, J S ^e   Park, S J ^f   Choi, C W ^f   Eom, H S ^g   Park, S K ^h   Choi, S Y ^b   Kim, S H ^b   Kim, D W ^a,b   Lee, S ^a,b  

^a Department of Hematology   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Chonnam National University Research Institute of Medical Sciences   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

^h Soonchunhyang University   (South Korea)

Author keywords

Acute lymphoblastic leukemia; Allogeneic stem cell transplantation; Dasatinib; Minimal residual disease; Philadelphia chromosome

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; MITOXANTRONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; TREATMENT OUTCOME; AGED; ALLOTRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; REMISSION; STEM CELL TRANSPLANTATION;

ADULT; AGED; DASATINIB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84974777815     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw123     Document Type: Article

References (20)

1. Thomas DA, Faderl S, Cortes J et al. Treatment of Philadelphia chromosomepositive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103(12): 4396-4407.
2. Yanada M, Takeuchi J, Sugiura I et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCRABL- positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24(3): 460-466.
3. Wassmann B, Pfeifer H, Goekbuget N et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphiapositive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108(5): 1469-1477.
4. de Labarthe A, Rousselot P, Huguet-Rigal F et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosomepositive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109(4): 1408-1413.
5. Fielding AK, Rowe JM, Buck G et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 2014; 123(6): 843-850.
6. Lee S, Kim YJ, Min CK et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105(9): 3449-3457.
7. Lee S, Kim DW, Cho BS et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012; 26(11): 2367-2374.
8. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305(5682): 399-401.
9. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354(24): 2531-2541.
10. Ottmann O, Dombret H, Martinelli G et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007; 110(7): 2309-2315.
11. Khoury HJ, Guilhot F, Hughes TP et al. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009; 115(7): 1381-1394.
12. Kang HY, Hwang JY, Kim SH et al. Comparison of allele specific oligonucleotidepolymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 2006; 91(5): 659-662.
13. Ravandi F, O'Brien S, Thomas D et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116(12): 2070-2077.
14. Foà R, Vitale A, Vignetti M et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118(25): 6521-6528.
15. Ravandi F, O'Brien SM, Cortes JE et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2015; 121(23): 4158-4164.
16. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26 (19): 3204-3212.
17. Chalandon Y, Thomas X, Hayette S et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood 2015; 125(24): 3711-3719.
18. Schultz KR, Bowman WP, Aledo A et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27(31): 5175-5181.
19. Ravandi F, Jorgensen JL, Thomas DA et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 2013; 122(7): 1214-1221.
20. Pfeifer H, Wassmann B, Pavlova A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110(2): 727-734.